Drug Interaction:
Macrolide antibiotics include-
Azithromycin. clarithromycin, dirithromycin, erythromycin and troleandomycin
Refer- Erythromycin
Interacting drugs- summary
Roxithromycin +
Pimozide / Terefenadine / Astemizole / Cisapride
Roxithromycin inhibits cytochrome P450 enzymes leading to decreased
metabolism resulling in increased serum concentration of these drugs.
Result in prolonged QT intervals, severe ventricular arrhythmias and
sudden death. Avoid concomittant administration of roxithromycin with
terfenadine, astemizole and cisapride.
Warfarin
Although roxithromycin has a lesser inhibiting effect on cytochrome P450
enymes than other macrolide antibiotics, roxithromycin may potentiate the effects of warfarin in severely ill elderly or compromised patients and increase risk of bleeding
Disopyramide
Roxithromycin displaces disopyramide from protein-binding sites in vitro.
Concurrent administration of these drugs in vivo resulted in increased
disopyramide serum concentration. Consequently ECG and if possible
disopyramide levels should be monitored
Midazolam
Roxithromycin may inhibit benzodiazepine metabolism, leading to
increased plasma concentration of benzodiapines toxicirty (CNS depression,
ataxia, lethargy)
Digoxin
Macrolide increases plasma concentration of digoxin resulting in
increased risk of toxicity. Serum dogoxin levels should be carefully
monitored when roxithromycin is added to or withdrawn from therapy
Theophylline
Caution should be excercised with patients receiving concomittant
theophylline therapy as roxithromycin may increase theophylline levels,
which lead to theophylline toxicity.
Indication:
Suscepible infections
Macrolide antibiotics include- Azithromycin. clarithromycin, dirithromycin, erythromycin and troleandomycin Refer- Erythromycin
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Roxithromycin Anti-bacterial March 1992
Adverse Reaction:
Anaphylactic reactions.
Nausea,abdominal pain, Diarrhoea, weakness, malaise, anorexia, Constipation, dyspepsia, Flatulance, malaena, Oral candidiasis, Vomiting, dizziness, tinnitus, Headache and vertigo.
Other Information:
For Availability/supplies
Contact -
1.Indian Drug Manufacturers Association (IDMA)
Phone- 022- 24944624/ 24974308
Fax- 022- 24950723
Email- idma@vsnl.com
Website: www.idma-assn.org
2.Bulk Drug Manufacturers Association (India)(BDMA)
Phone - 040-23703910/ 23706718
Fax- 040-23704804
Email- info@bdmai.org
Website: www.info@bdmai.org
Manufacturer Details